Enrolling Studies

Sponsored by Accera

A 26 Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants with Mild to Moderate Alzheimer’s Disease (AD) with an Optional 26 -Week Open-Label Extension

Sponsored by Lundbeck

Randomized, double-blind, parallel-group, placebo controlled, fixed dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with acetylcholinesterase inhibitor; Study 3

Please contact Juanita M Smith, Senior Research Coordinator at 732-657-6100 or fill out the form below with any questions regarding the above.

Your Name (required)

Your Email (required)

Your Phone (required)

Subject

Your Message